Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, August 4, 2022
[ Thu, Aug 04th 2022
] - WOPRAI
[ Thu, Aug 04th 2022
] - WOPRAI
[ Thu, Aug 04th 2022
] - WOPRAI
[ Thu, Aug 04th 2022
] - WOPRAI
[ Thu, Aug 04th 2022
] - WOPRAI
[ Thu, Aug 04th 2022
] - WOPRAI
Wed, August 3, 2022
[ Wed, Aug 03rd 2022
] - WOPRAI
[ Wed, Aug 03rd 2022
] - WOPRAI
[ Wed, Aug 03rd 2022
] - WOPRAI
[ Wed, Aug 03rd 2022
] - WOPRAI
[ Wed, Aug 03rd 2022
] - WOPRAI
[ Wed, Aug 03rd 2022
] - WOPRAI
[ Wed, Aug 03rd 2022
] - WOPRAI
[ Wed, Aug 03rd 2022
] - WOPRAI
[ Wed, Aug 03rd 2022
] - WOPRAI
[ Wed, Aug 03rd 2022
] - WOPRAI
[ Wed, Aug 03rd 2022
] - WOPRAI
[ Wed, Aug 03rd 2022
] - WOPRAI
[ Wed, Aug 03rd 2022
] - WOPRAI
[ Wed, Aug 03rd 2022
] - WOPRAI
[ Wed, Aug 03rd 2022
] - WOPRAI
[ Wed, Aug 03rd 2022
] - WOPRAI
[ Wed, Aug 03rd 2022
] - WOPRAI
[ Wed, Aug 03rd 2022
] - WOPRAI
[ Wed, Aug 03rd 2022
] - WOPRAI
[ Wed, Aug 03rd 2022
] - WOPRAI
[ Wed, Aug 03rd 2022
] - WOPRAI
[ Wed, Aug 03rd 2022
] - WOPRAI
[ Wed, Aug 03rd 2022
] - WOPRAI
[ Wed, Aug 03rd 2022
] - WOPRAI
Judah Frommer Maintained (SRPT) at Hold with Increased Target to $93 on, Aug 3rd, 2022
Judah Frommer of Credit Suisse, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Hold with Increased Target from $90 to $93 on, Aug 3rd, 2022.
Judah has made no other calls on SRPT in the last 4 months.
There are 3 other peers that have a rating on SRPT. Out of the 3 peers that are also analyzing SRPT, 0 agree with Judah's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Judah
- Gil Blum of "Needham" Maintained at Strong Buy with Increased Target to $162 on, Friday, July 29th, 2022
- Kristen Kluska of "Cantor Fitzgerald" Maintained at Buy with Decreased Target to $128 on, Friday, June 24th, 2022
- Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Increased Target to $107 on, Tuesday, April 19th, 2022
